Erythropoietic protoporphyria (EPP) is a rare inherited disorder caused by a defect in heme synthesis. This pathology is characterized by the accumulation of porphyrin precipitates in red blood cells and other tissues, which leads to various clinical manifestations. The main symptoms include photosensitivity, skin manifestations such as hyperemia and edema caused by exposure to sunlight. EPP can be a significant problem for the patient, since severe skin burns are possible due to photosensitivity, as well as other systemic disorders associated with an increase in the level of porphyrins in the body.
History of the disease and interesting historical facts
Erythropoietic protoporphyria was first described in the scientific literature in the mid-20th century, when unusual cases of people with severe photosensitivity and associated skin problems attracted the attention of physicians. In the 20th century, gene mutations responsible for the development of this disease were identified. An interesting historical fact is that in ancient times, symptoms comparable to EPP could be misinterpreted as curses or manifestations of witchcraft, which contributed to the stigmatization of those affected. EPP as a genetic disease was finally determined only with the development of molecular genetics and discoveries in the field of biochemistry.
Epidemiology
Erythropoietic protoporphyria has a low prevalence, with estimates suggesting that there may be 1-3 cases per 100,000 population. The disorder is significantly more common in certain populations, which is thought to be related to a high frequency of mutations in genes involved in heme synthesis. The most prominent cohorts are found in countries with high genetic isolation, such as Finland and some other Nordic countries. EPP has remained undiagnosed for a long time, further complicating efforts to obtain comprehensive epidemiological data.
Genetic predisposition to this disease
Erythropoietic protoporphyria is caused by mutations in the FECH gene, which codes for an enzyme involved in the final step of heme biosynthesis. In most cases, the disorder is transmitted in an autosomal recessive manner, meaning that two mutant alleles are required for the disorder to manifest. Mutations can range from point mutations to deletions, and a significant proportion are associated with higher levels of porphyrin precipitates in the blood. Genetic testing can confirm the diagnosis and provide counseling for family members.
Risk factors for the development of this disease
Despite the genetic nature of EPP, there are several external factors that can provoke its exacerbation. The main risk factors include:
- Physical effects: excessive ultraviolet radiation, which can cause exacerbations of photosensitivity.
- Chemical factors: use of certain cosmetics and perfumes containing photosensitizers.
- Other medical conditions: Concomitant diabetes or liver disease may also worsen the symptoms of EPP.
Diagnosis of this disease
Various methods are used to diagnose erythropoietic protoporphyria. The main symptoms include:
- Photosensitivity with accompanying skin lesions: eczema, edema and hyperpigmentation.
- Nutritional and developmental disorders in children.
- Frequent temperature rises and general malaise after sun exposure.
Laboratory tests include measuring porphyrin levels in the blood and urine. Radiological examinations may be used to evaluate the internal organs in patients with severe forms of the disease. It is also important to differentiate other porphyrias and look for possible causes of photosensitivity, such as skin diseases or systemic disorders.
Treatment
Treatment of erythropoietic protoporphyria is mainly symptomatic. The main approaches include:
- General treatment: avoid direct sunlight, use protective clothing and high SPF creams.
- Pharmacological treatment: if necessary, anti-inflammatory drugs and steroids are prescribed during the acute period of the disease.
- Surgical treatment: In cases of severe skin lesions, surgical correction may be required.
- Other treatments: Phototherapy may be used with caution to reduce the effects of photosensitivity.
List of medications used to treat this disease
The most commonly used medications include:
- Corticosteroids to reduce skin inflammation.
- Drugs to improve heme metabolism, such as iron chelators.
- Systemic antihistamines to control allergic reactions.
Disease monitoring
Monitoring of patients with EPP includes regular examinations by a dermatologist and a hematologist. The prognosis often depends on the severity of the disease and the level of porphyrins in the blood. Possible complications can range from skin infections to systemic disorders associated with severe forms of the disease, which can lead to significant disability of the patient.
Age-related features of the disease
Erythropoietic protoporphyria can occur at any age, but the greatest number of cases are recorded in children and young adults. In children, the disease often manifests itself more clearly due to high activity and significant time spent in the sun. Adult patients clearly understand the need for precautions and restrictions, but older people are at higher risk of developing concomitant diseases, which can worsen the course of EPP.
Questions and Answers
- What are the main symptoms of EPP? The main symptoms include extreme sensitivity to light, skin rashes after exposure to sunlight, and general weakness and fatigue.
- How to diagnose EPP? Diagnosis includes blood tests for porphyrin levels, assessment of the immune status, and genetic testing to confirm mutations.
- Which treatment is most effective? Treatment is mainly symptomatic, including avoiding sunlight and using anti-inflammatory therapy during flare-ups.
- What are the potential complications of EPP? Complications may include skin infections, chronic dermatological pathologies and, in rare cases, the development of other systemic diseases.
- Can EPP be prevented? Prevention usually involves avoiding known triggers, such as sunlight, but the disease cannot be completely prevented.
Advice from Dr. Oleg Korzhikov
"Erythropoietic protoporphyria requires special attention and understanding from the patient. The most important thing is to follow simple but effective recommendations. I advise you to avoid sun rays, especially during the hours of their maximum activity. Be sure to use sunscreens with a high SPF level and wear appropriate clothing. Make sure that you are regularly examined by specialists to learn about the status of your porphyrins and receive the correct treatment. Discuss your symptoms with your doctor, even if they seem minor, as this can help to avoid serious consequences."
